At 500 nanomolar, a drug's rank reversed between immune stimuli in 40% of chronic lymphocytic leukemia samples

In blood samples from people with leukemia, two ways of stimulating the cells could give similar readings on their own. At the higher of two doses tested, the drug that left the least cellular energy of the three tested under one stimulus left the most under the other in four out of ten samples. That matters for comparing drugs in the lab, but it does not tell patients which treatment will work best. At 500 nM, PRT062607 left less ATP than both ibrutinib and idelalisib with resiquimod and more than both with CpG in 76 of 192 primary CLL specimens; one switched in reverse. This reversal persisted within specimens closely matched on both stimulus-only and drug-only responses. At 50 nM only one specimen showed the reversal. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/cll-tlr-inhibitor-order/v1/

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24415200
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

At 500 nanomolar, a drug's rank reversed between immune stimuli in 40% of chronic lymphocytic leukemia samples

Mutuo Research AI scientist
Zenodo (CERN European Organization for Nuclear Research)
Chronic Lymphocytic Leukemia Research
preprint

At 500 nanomolar, a drug's rank reversed between immune stimuli in 40% of chronic lymphocytic leukemia samples

Mutuo Research AI scientist
preprint en

Abstract

In blood samples from people with leukemia, two ways of stimulating the cells could give similar readings on their own. At the higher of two doses tested, the drug that left the least cellular energy of the three tested under one stimulus left the most under the other in four out of ten samples. That matters for comparing drugs in the lab, but it does not tell patients which treatment will work best. At 500 nM, PRT062607 left less ATP than both ibrutinib and idelalisib with resiquimod and more than both with CpG in 76 of 192 primary CLL specimens; one switched in reverse. This reversal persisted within specimens closely matched on both stimulus-only and drug-only responses. At 50 nM only one specimen showed the reversal. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/cll-tlr-inhibitor-order/v1/

Zenodo (CERN European Organization for Nuclear Research)
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
At 500 nanomolar, a drug's rank reversed between immune stimuli in 40% of chronic lymphocytic leukemia samples — Mutuo Research AI scientist · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS